Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | PAK4 | O96013 | 5/20 | 0.60 |
| ▸ | PLK4 | O00444 | 4/20 | 0.60 |
| ▸ | AURKA | O14965 | 9/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.57 |
| ▸ | JAK2 | O60674 | 4/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.57 |
| ▸ | JAK3 | P52333 | 4/20 | 0.57 |
| ▸ | IGF1R | P08069 | 4/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.57 |
| ▸ | RET | P07949 | 2/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.57 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.57 |
| ▸ | STK10 | O94804 | 1/20 | 0.57 |
| ▸ | FER | P16591 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218565 | 0.88 | PAK4 (0.60) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL219273 | 0.85 | IGF1R (0.62) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL4005596 | 0.85 | MEN1 (0.59) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL219315 | 0.85 | PLK4 (0.58) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL1770945 | 0.84 | FGFR1 (0.46) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL14771711 | 0.83 | PLK4 (0.55) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL218975 | 0.82 | PLK4 (0.54) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL4040276 | 0.82 | FGFR1 (0.46) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL4041620 | 0.81 | NTRK1 (0.46) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL3337463 | 0.81 | MEN1 (0.42) | MEN1HTTKMT2AHSD17B10PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221798-B2 | 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof | Zhejian Hisun Pharmaceutical Co., Ltd. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-9221798-B2 | 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof | Zhejian Hisun Pharmaceutical Co., Ltd. (CN) | 2015-12-29 | — | — | US | disclosed |
| WO-2015094803-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-06-25 | — | — | WO | disclosed |
| CN-104693189-A | Pyrimidine compound and preparation method and application thereof | LIU QIANG | 2015-06-10 | — | — | CN | disclosed |
| CN-104693188-A | Pyrimidine compound and synthesis method and application thereof | LIU QIANG | 2015-06-10 | — | — | CN | disclosed |
| US-20140378488-A1 | 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2014-12-25 | — | — | US | disclosed |
| US-20140378488-A1 | 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2014-12-25 | — | — | US | disclosed |
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| EP-1945631-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| US-20080161330-A1 | Pyrimidines as Igf-I Inhibitors | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| EP-1899323-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1869028-A1 | PYRIMIDINES AS IGF-I INHIBITORS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007049041-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | WO | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| WO-2006123113-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006106306-A1 | PYRIMIDINES AS IGF-I INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| EP-1678169-A1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040159-A1 | 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378488-A1 | 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF | MAP4K2, MAP4K1, MAP4K3 | MEN1 3411/4885HTT 4639/4885KMT2A 3065/4885 |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | IGF1R, IGFBP1, GPR119 | MEN1 2736/4885HTT 4461/4885KMT2A 3659/4885 |
| US-20080161330-A1 | Pyrimidines as Igf-I Inhibitors | IGF1R, IGFBP1, IGFBP2 | MEN1 1093/4885HTT 3518/4885KMT2A 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.